血液科

订阅

MedSci主页 / 所有栏目 / 血液科

J Clin Oncol：采用KTE-X19治疗复发/难治性套细胞淋巴瘤的3年随访结果

2022-06-11 MedSci原创 MedSci原创

套细胞淋巴瘤KTE-X19Brexucabtagene autoleucel
关注

KTE-X19在复发/难治性套细胞淋巴瘤患者中可诱导持久的长期缓解

Brexucabtagene autoleucel (KTE-X19) 自体抗 CD19 嵌合抗原受体 (CAR) T 细胞疗法已被批准用于治疗复发/难治性套细胞淋巴瘤 (MCL)。ZUMA-2研究是一项关于KTE-X19的飞行试验，评估了其在复发/难治性MCL患者中的初步活性。本文汇报了该研究随访3年时的预后。

在该研究中，既往接受过1-5次治疗（包括Bruton酪氨酸激酶抑制剂[BTKi]）的复发性/难治性MCL患者接受了一剂KTE-X19（2x106个CAR T细胞/kg）。


不同反应患者的缓解持续时间

共招募了68位患者，均接受了研究治疗。中位随访了35.6个月后，客观缓解率为91%，其中68%的患者获得了完全缓解。中位缓解持续时间是28.2个月，无进展生存期和总生存期分别是25.8个月和46.6个月。


不同反应患者的无进展生存率

事后分析表明，客观缓解率和持续缓解率在预定的有无BTKi暴露或高风险特征的亚组中保持一致。在探索性分析中，既往使用苯达莫司汀的患者可从KTE-X19中受益，但会表现出T细胞功能减弱的趋势，在白细胞分离术后的6个月内给予苯达莫司汀的影响比12个月内更大。


不同反应患者的总生存率

迟发性毒性不常见；仅3%的患者出现不良事件。转化评估揭示了与KTE-X19长期益处相关的因素，包括应答者CAR T细胞扩增的高峰值，以及微小残留病灶对复发的预测价值。

综上，据了解，这是迄今为止关于MCL患者进行CAR T细胞治疗的最长随访时间；研究结果提示，KTE-X19在复发/难治性MCL患者中可诱导持久的长期缓解，安全性可控，而且还可能使具有高风险特征的患者受益。

原始出处：

Michael Wang, et al. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. Journal of Clinical Oncology. June 04, 2022. https://ascopubs.org/doi/full/10.1200/JCO.21.02370

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1866630, encodeId=4ff918666302c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Dec 22 11:10:09 CST 2022, time=2022-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818835, encodeId=366d181883565, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 20 06:10:09 CST 2023, time=2023-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702716, encodeId=a4491e02716f5, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Mon Oct 31 13:10:09 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528876, encodeId=7a8e15288e61c, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu Jun 09 13:10:09 CST 2022, time=2022-06-09, status=1, ipAttribution=)]
    2022-12-22 minlingfeng

    #Oncol#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1866630, encodeId=4ff918666302c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Dec 22 11:10:09 CST 2022, time=2022-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818835, encodeId=366d181883565, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 20 06:10:09 CST 2023, time=2023-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702716, encodeId=a4491e02716f5, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Mon Oct 31 13:10:09 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528876, encodeId=7a8e15288e61c, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu Jun 09 13:10:09 CST 2022, time=2022-06-09, status=1, ipAttribution=)]
    2023-01-20 维他命

    #随访结果#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1866630, encodeId=4ff918666302c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Dec 22 11:10:09 CST 2022, time=2022-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818835, encodeId=366d181883565, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 20 06:10:09 CST 2023, time=2023-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702716, encodeId=a4491e02716f5, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Mon Oct 31 13:10:09 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528876, encodeId=7a8e15288e61c, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu Jun 09 13:10:09 CST 2022, time=2022-06-09, status=1, ipAttribution=)]
    2022-10-31 marlenexl

    #细胞淋巴瘤#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1866630, encodeId=4ff918666302c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Dec 22 11:10:09 CST 2022, time=2022-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818835, encodeId=366d181883565, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 20 06:10:09 CST 2023, time=2023-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702716, encodeId=a4491e02716f5, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Mon Oct 31 13:10:09 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528876, encodeId=7a8e15288e61c, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu Jun 09 13:10:09 CST 2022, time=2022-06-09, status=1, ipAttribution=)]
    2022-06-09 freve

    #难治性#

    0

相关资讯

Blood：泽布替尼治疗复发/难治性套细胞淋巴瘤的长期疗效

复发性/难治性套细胞淋巴瘤患者采用泽布替尼治疗可获得持久的缓解，且具有很好的安全性

Lancet Oncol：依鲁替尼-利妥昔单抗诱导治疗可减少套细胞淋巴瘤的化疗疗程

依鲁替尼-利妥昔单抗诱导方案用作年轻套细胞淋巴瘤患者的一线治疗有效且安全

J Clin Oncol：依鲁替尼联合利妥昔单抗一线治疗套细胞淋巴瘤老年患者的疗效

依鲁替尼与利妥昔单抗的联合方案可有效治疗套细胞淋巴瘤老年患者

NICE：欧洲套细胞淋巴瘤患者将从CAR-T细胞疗法中全面受益！

Tecartus是一种CD19靶向的CAR-T细胞疗法。

Leukemia：环状RNA在套细胞淋巴瘤中的表达模式和预后潜力

套细胞淋巴瘤（MCL）是非霍奇金淋巴瘤的一种亚型，属于B细胞淋巴瘤。

Blood：LRPAP1自身抗体阳性的套细胞淋巴瘤患者预后相对较好！

LRPAP1自身抗体血清阳性的套细胞淋巴瘤患者的临床治疗结果更好，LRPAP1自身抗体或可作为套细胞淋巴瘤患者的一个预后预测指标